Publications by authors named "Ed Hsiao"
Pulmonary BRAF-driven Langerhans cell histiocytosis following selpercatinib use in metastatic medullary thyroid cancer.
Endocrinol Diabetes Metab Case Rep
April 2024
Article Synopsis
- RET mutations are found in 60% of medullary thyroid cancer cases and the drug selpercatinib shows significant effectiveness against it compared to older treatments.
- A 22-year-old woman with metastatic medullary thyroid cancer improved with selpercatinib, but later developed lung nodules diagnosed as Langerhans cell histiocytosis, which had a rare BRAF mutation.
- The authors suggest that the use of RET inhibitors like selpercatinib might cause dormant BRAF mutations to activate, leading to new cancers due to changes in the MAPK signaling pathway.
Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer.
Asia Pac J Clin Oncol
August 2018
Aim: To explore the utility of prostate specific membrane antigen (PSMA)-positron emission tomography (PET)/computed tomography (CT) in addition to conventional imaging prior to definitive external beam radiation treatment (EBRT) for prostate cancer.
Methods: All men undergoing PSMA-PET/CT prior to definitive EBRT for intermediate and high-risk prostate cancer were included in our ethics approved prospective database. For each patient, clinical and pathological results, in addition to scan results including site of PSMA positive disease and number of lesions, were recorded.
Purpose: To identify sites of failure with Ga-PSMA-PET (PSMA-PET) imaging in patients who have Biochemical Failure (BF) following post-prostatectomy radiotherapy.
Material And Methods: Between June 2006 and January 2016, 409 men received post prostatectomy intensity modulated radiation treatment (IMRT) with protocolised planning. 310 patients received radiation treatment (RT) to the Prostate Fossa (PF) alone and 99 patients received RT to PF and pelvic lymphatics (PF + LN) usually in combination with androgen deprivation (AD) therapy.
Background And Purpose: We investigated the role of Ga-PSMA-PET (PSMA) to determine the location of disease recurrence in those with a rising PSA following definitive external beam radiation treatment (EBRT).
Materials And Methods: 538men were treated with image guided EBRT to a dose of 78 or 82Gy between 2007 and 2014. Patients at least 24months post EBRT with biochemical failure (nadir+2) underwent PSMA scanning.